Anderson Woodrow D purchased $54K of INDV

Anderson Woodrow D (Chief Accounting Officer) purchased 1,500 shares of Indivior Pharmaceuticals, Inc. (INDV) at $36.28 on 2026-08-05.

Original reporting
SEC EDGAR · Anderson Woodrow D
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INDV
Bullish
low confidence
Mentioned
$INDV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INDVBullishLow
01

Why it matters

Traders may monitor for follow-on insider activity, but the filing alone does not change fundamentals or near-term expectations.

02

Market read

A routine insider open-market buy was disclosed, offering only a modest sentiment signal.

03

What to watch

The transaction is small relative to company size and lacks any stated rationale; without follow-on buys or company guidance, signal strength is weak.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-05, after-hours/close timing for traders to note

Background

The article is a SEC Form 4 insider transaction disclosure for Indivior Pharmaceuticals, Inc.

Company-level read

Ticker impact

$INDVBullishLow confidence
Context

Indivior disclosed a Form 4 showing Chief Accounting Officer Anderson Woodrow D bought 1,500 shares at $36.2800 on 2026-08-05.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan and no accompanying company-specific operational or financial disclosure.

Market effects

No clear sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider purchases can be discretionary and may reflect diversification or personal liquidity needs rather than a strong earnings outlook.

Key entities

  • Indivior Pharmaceuticals, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Anderson Woodrow D

    Chief Accounting Officer who reported an open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SUPNMed

Supernus undervalued after Indivior merger, says Bank of America

Bank of America initiated coverage of Supernus Pharmaceuticals (SUPN) with a 'buy' rating and $47 price target, citing its merger with Indivior. The combined entity is expected to have a broader portfolio and stronger earnings potential. Bank of America forecasts 6% annual revenue and EPS growth over five years, with legacy Supernus products driving two-thirds of revenue growth.

$SUPNHighAI 9/10

Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

Supernus Pharmaceuticals (SUPN) and Indivior completed their merger, creating Supernus, Inc. The combined company will trade on Nasdaq under 'SUPN' starting November 3, 2026. The merger enhances financial flexibility, expands the CNS-focused portfolio, and positions the company for long-term growth. Former Indivior shareholders will receive a $1 billion cash dividend, financed by debt and existing cash.

$INDVHighAI 8/10

Why Indivior Pharmaceuticals Stock Topped the Market Today

Indivior Pharmaceuticals (NASDAQ:INDV) shares rose 3% on its last day as a standalone company after completing a merger with Supernus Pharmaceuticals (NASDAQ:SUPN). The combined company, to be named Supernus, aims for $125M in annual cost synergies, with Indivior shareholders owning 56.5% of the new entity.

$SUPNHighAI 8/10

Supernus Pharmaceuticals Completes Merger with Indivior Pharmaceuticals

Supernus Pharmaceuticals (SUPN) completed its merger with Indivior Pharmaceuticals on November 2, 2026, forming Supernus, Inc. The combined company has an 11-product portfolio and headquarters in Rockville, Maryland. Supernus stockholders received 1.5401 Indivior shares per Supernus share. The company borrowed $650 million to fund a $1 billion dividend to Indivior stockholders.

$INDVHighAI 9/10

Indivior Pharmaceuticals, Inc. (INDV): Completion of Acquisition or Disposition of Assets

Indivior Pharmaceuticals, Inc. (INDV) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader · Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flex